AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Fiserv Plunges 16.95% on Revenue Growth Miss
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jul 23, 2025 8:33 am ET1min read
Aime SummaryOn July 23, 2025, Fiserv's stock experienced a significant drop of 16.95% in pre-market trading.
Fiserv's stock price plummeted after the company reported disappointing organic revenue growth for the second quarter. The payment technology firm revised its full-year organic growth forecast downward, citing underperformance in key areas. This news sent shockwaves through the market, leading to a substantial decline in investor confidence.
Despite the revenue shortfall, Fiserv's second-quarter earnings showed a year-over-year increase, surpassing analysts' expectations. The company reported adjusted earnings of $2.47 per share, slightly above the anticipated $2.43 per share. However, the positive earnings report was overshadowed by the disappointing revenue growth, which failed to meet market expectations.
Looking ahead, Fiserv's CEO, Mike Lyons, acknowledged the need for refinements in the company's guidance based on current performance and business activity levels. The company now expects organic revenue growth of around 10% for the full year, with adjusted earnings per share ranging from $10.15 to $10.30. This represents a slight adjustment from the previous projection of 10% to 12% organic revenue growth and the same earnings per share range.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet